-
Arellano et al. Blood. Aug 28 2025;146(9):1065–1077. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
-
Revumenib prescribing information
absolute neutrophil count; ANC; acute leukemia; ALL; alloSCT; AML; adverse event management; AE; AUGMENT 101; AUGMENT-101; black box; differentiation syndrome; DS; dose; efficacy; exposure response; HSCT; inducer; inhibitor; interaction; interactions; KMT2A; KMT2Ar; KMT2At; lymphoblastic; management; mechanism; mixed phenotype; mixed-phenotype; MOA; monotherapy; MPAL; pediatric; peds; pharmacokinetics; pk; prescribing information; QT; QTC; rearranged; refractory; relapsed; Revuforj; translocated;…
-
Revumenib QTc Prolongation MED-REV-250047
-
Revumenib Safety Data Sheet
-
Revumenib Pharmacokinetics MED-REV-240027
-
Revumenib Monotherapy in KMT2Ar RR AL MED-REV-240021
-
Aldoss et al. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia. Presented at EHA 2025
-
Issa et al. J Clin Oncol. 2025 Jan;43(1):75-84. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
-
Revumenib Pediatrics MED-REV-240029
-
Revumenib AE Management MED-REV-240014
-
Revumenib Monotherapy in NPM1m RR AML MED-REV-240026
-
Arellano et al. Revumenib for Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Phase 2 AUGMENT-101 Study. Presented at the 30th Annual Congress of the European Hematology Association; 12–15 June 2025; Milan, Italy.
-
Revumenib Maintenance MED-REV-240028
-
Revumenib Combination Use MED-REV-240030